Paul Stoffels: Latest News

All news where Paul Stoffels is mentioned

02.07.2021 / 13:01

Delta variant: J&J vaccine provides ‘strong’ protection, preliminary study says

NEW BRUNSWICK, N.J. - Johnson & Johnson announced on Thursday that preliminary data shows their one-shot COVID-19 vaccine provides "strong" protection against the delta variant, according to a company news release. In addition, the company stated their vaccine provides a durable immune response for at least eight months against the delta variant, which researchers believe to be more transmissible than previously discovered variants. "Today’s newly announced studies reinforce the ability of the Johnson & Johnson COVID-19 vaccine to help protect the health of people globally," said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer at Johnson & Johnson.

Paul Stoffels state New Jersey county Brunswick county Johnson city New Brunswick, state New Jersey covid-19 vaccine Health

Johnson & Johnson says its single-shot Covid vaccine protects against Delta variant

Johnson & Johnson Covid-19 vaccine produces a strong response against the Delta variant of the virus, the company has said.

Paul Stoffels India virus covid-19 vaccine

J&J's top scientist Paul Stoffels on their Covid vaccine's 'secret sauce'

AFP: What makes the J&J vaccine such an important tool?Stoffels: The vaccine we just got approved by the European authorities is a single-shot vaccine, and it's the first vaccine which was studied on a very large scale (around 40,000 people), including the variants.

Paul Stoffels Usa India South Africa hospital vaccine HIV

J&J COVID vaccine heads to FDA for emergency use decision

Late yesterday Johnson & Johnson submitted a request for an emergency use authorization (EUA) for its COVID-19 candidate. If the EUA is granted by the Food and Drug Administration (FDA), the vaccine will become the third COVID-19 vaccine approved for use in the United States, and the first that requires only one dose.

Paul Stoffels Usa covid-19 vaccine mask

One-shot Covid-19 vaccine is step closer with Johnson Johnson asking for US approval

The world's very first single-dose coronavirus vaccine for emergency use "is a pivotal step toward".

Paul Stoffels Usa Britain county Johnson covid-19 vaccine Coronavirus

Johnson & Johnson’s single-shot coronavirus vaccine on track for March, exec says

Johnson & Johnson is on track to roll out its single-shot coronavirus vaccine in March, and expects to have clear data on how effective it is by the end of this month or early February, the U.S. healthcare company’s chief scientific officer said.

Paul Stoffels covid-19 Coronavirus Johnson & Johnson track

J&J expects data for US authorisation of coronavirus vaccine by February

coronavirus vaccine, US drugmaker Johnson & Johnson's chief scientist said the company is recruiting more than 1,000 people per day. The drug firm also expects to have all the data needed to seek US authorisation by February next year or earlier."By the end of the year or around the end of the year, we should have 60,000 people in the study," news agency Reuters quoted J&J's chief scientific officer Dr.

Paul Stoffels Usa county Johnson virus covid-19 vaccine Coronavirus

Drug companies work jointly to boost coronavirus vaccine confidence

LONDON – Two firms developing COVID-19 vaccines say pharmaceutical companies are trying to give the public as much information as possible about their testing regimes as drugmakers and public health officials seek to boost confidence that any approved vaccine will be safe.AstraZeneca CEO Pascal Soriot and Paul Stoffels, chief scientific officer of Johnson & Johnson, said Thursday that they recognize the coronavirus emergency demands increased transparency from vaccine developers to ensure the public has faith in the end product.

Paul Stoffels Pascal Soriot information vaccine Coronavirus

Johnson & Johnson ramps up production of affordable Covid-19 vaccine, human trials to begin soon

Kolkata: Johnson & Johnson is preparing the ground for the entry of a vaccine against COVID-19 and is expanding its manufacturing capacity to supply more than one billion doses through 2021 in a not-for-profit project aimed at the common person, says its top scientist.The US-based pharma giant, which has already advanced its schedule of starting human trials of its candidate vaccine to the second half of July from September, is working on the twin fronts of expanding existing manufacturing capacity and establishing new units, Chief Scientific Officer Paul Stoffels told PTI."We plan to begin production at risk and are committed to bringing an affordable vaccine to the public on a not-for-profit basis for emergency pandemic use.

Paul Stoffels Usa city Kolkata covid-19 testing pandemic vaccine

Race for coronavirus vaccine draws billions of dollars worldwide, with focus on speed

In the race to develop a vaccine to end the COVID-19 pandemic, governments, charities and Big Pharma firms are sinking billions of dollars into bets with extraordinarily low odds of success.

Paul Stoffels covid-19 World Health Organization Coronavirus vaccines

United States	Cases: 46 252 513 Deaths: 750 423 Recovered: 0
India	Cases: 34 321 025 Deaths: 459 652 Recovered: 0
Brazil	Cases: 21 835 785 Deaths: 608 235 Recovered: 0
United Kingdom	Cases: 9 215 683 Deaths: 141 607 Recovered: 0
Russia	Cases: 8 494 589 Deaths: 237 619 Recovered: 0